Body mass index (BMI) and outcome of metastatic melanoma patients receiving targeted therapy and immunotherapy: a multicenter international retrospective study
Piotr Rutkowski(The Maria Sklodowska-Curie National Research Institute of Oncology), Mario Mandalà(University of Perugia), Paweł Teterycz(National Institute of Oncology), Anna Mariuk-Jarema(National Institute of Oncology), Barbara Merelli(Ospedale Papa Giovanni XXIII), Lorenza Di Guardo(Fondazione IRCCS Istituto Nazionale dei Tumori), Alice Labianca(Ospedale Papa Giovanni XXIII), Paweł Rogala(National Institute of Oncology), Iwona Ługowska(The Maria Sklodowska-Curie National Research Institute of Oncology), Carlo Tondini(Ospedale Papa Giovanni XXIII), Jacopo Pigozzo(Istituto Oncologico Veneto), Eliana Rulli(Mario Negri Institute for Pharmacological Research), Francesca Corti(Fondazione IRCCS Istituto Nazionale dei Tumori), Giovanni Randon(Fondazione IRCCS Istituto Nazionale dei Tumori), Bożena Cybulska-Stopa(The Maria Sklodowska-Curie National Research Institute of Oncology), Michele Del Vecchio(Fondazione IRCCS Istituto Nazionale dei Tumori), Matilde De Luca(Mario Negri Institute for Pharmacological Research), Alice Indini(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico)
Cited by 60
Related Papers
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
|The Lancet|2012|3k
Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
|New England Journal of Medicine|2014|2.7k
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
|New England Journal of Medicine|2017|2.2k
Combined Vemurafenib and Cobimetinib in <i>BRAF</i> -Mutated Melanoma
|New England Journal of Medicine|2014|2k